patient subgroup...
Age < 65y (younger) Age > 65y Age > 75y (older) cell type, non squamous cell cell type, squamous cell ECOG 0 ECOG 1 Gender, female Gender, male metastasis (brain) NO metastasis (brain) YES PD-L1 < 1% PD-L1 < 10% PD-L1 < 5% PD-L1 > 1% PD-L1 > 10% PD-L1 > 5% PDL1 (TC3 or IC3 : ≥50% of TC or ≥10% of IC ) smoker (current or former) smoker (Current) smoker (Former) smoker (never)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
lung cancer : non small cell (NSCLC), nivolumab based treatment versus platinum association, meta-analysis of study results
Outcome
Relative effect 95%CI
LoD
Trt. better when
I2
k (RCT/OBS)
Bayesian probability
Overall ROB
Publication bias
Degree of certainty
Endpoint importance
Published MA
efficacy endpoints 00 deaths (OS) 0.78 [0.60, 1.02]< 1 0% 1 study (1/-) 96.7 % NA not evaluable crucial - progression or deaths (PFS) 0.73 [0.56, 0.95]< 1 0% 1 study (1/-) 99.0 % NA not evaluable important - safety endpoints 00 STRAE (any grade) 1.75 [1.00, 3.09]< 1 0% 1 study (1/-) 2.6 % NA not evaluable non important - STRAE (grade 3-4) 2.05 [1.12, 3.76]< 1 0% 1 study (1/-) 1.0 % NA not evaluable non important - TRAE (any grade) 3.42 [1.76, 6.65]< 1 0% 1 study (1/-) 0.0 % NA not evaluable non important - TRAE (grade 3-4) 2.35 [1.53, 3.60]< 1 0% 1 study (1/-) 0.0 % NA not evaluable non important - TRAE leading to death (grade 5) 4.33 [0.48, 39.16]< 1 0% 1 study (1/-) 9.7 % NA not evaluable non important - TRAE leading to discontinuation (any grade) 0.89 [0.48, 1.63]< 1 0% 1 study (1/-) 65.2 % NA not evaluable non important - TRAE leading to discontinuation (grade 3-4) 0.80 [0.38, 1.70]< 1 0% 1 study (1/-) 72.1 % NA not evaluable non important - TRAE (grade 3-4) endpoints 00 Anaemia TRAE (grade 3-4) 1.34 [0.75, 2.38]< 1 0% 1 study (1/-) 16.3 % NA not evaluable non important - Asthenia TRAE (grade 3-4) 1.06 [0.07, 17.15]< 1 0% 1 study (1/-) 48.3 % NA not evaluable non important - Constipation TRAE (grade 3-4) 0.26 [0.01, 5.89]< 1 0% 1 study (1/-) 79.7 % NA not evaluable non important - Decreased appetite TRAE (grade 3-4) 1.43 [0.32, 6.48]< 1 0% 1 study (1/-) 32.2 % NA not evaluable non important - Diarrhoea TRAE (grade 3-4) 1.06 [0.15, 7.64]< 1 0% 1 study (1/-) 47.5 % NA not evaluable non important - Fatigue TRAE (grade 3-4) 2.18 [0.65, 7.39]< 1 0% 1 study (1/-) 10.5 % NA not evaluable non important - Nausea TRAE (grade 3-4) 0.85 [0.22, 3.21]< 1 0% 1 study (1/-) 59.6 % NA not evaluable non important - Neutropenia TRAE (grade 3-4) 1.19 [0.63, 2.24]< 1 0% 1 study (1/-) 29.4 % NA not evaluable non important - Pruritus TRAE (grade 3-4) 1.06 [0.02, 53.93]< 1 0% 1 study (1/-) 48.8 % NA not evaluable non important - Rash TRAE (grade 3-4) 2.13 [0.07, 64.04]< 1 0% 1 study (1/-) 33.3 % NA not evaluable non important - Vomiting TRAE (grade 3-4) 1.43 [0.32, 6.48]< 1 0% 1 study (1/-) 32.2 % NA not evaluable non important -
LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias;
suggested: nominally statistically significant but without a strict control of overall risk of type 1 error;
inconclusive: not nominally statistically significant;
safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies;
published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE.
Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.